| ［1］ Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010［J］. CA Cancer J Clin, 2010, 60(5): 277300. DOI: 10.3322/caac.20073. ［2］ Bladé J, de Larrea CF, Rosiol L, et al. Extramedullary involvement in multiple myeloma ［J］. Haematologica, 2012, 97(11): 16181619. DOI: 10.3324/haematol.2012.078519. ［3］ Bladé J, Fernández de Larrea C, Rosiol L, et al. Softtissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullaryspread, and treatment approach［J］. J Clin Oncol, 2011, 29(28): 38053812. DOI: 10.1200/JCO.2011.34.9290. ［4］ Ghobrial IM. Myeloma as a model for the process of metastasis: implicationgs for therapy［J］. Blood, 2012, 120(1): 2030. DOI: 10.1182/blood201201379024. ［5］ Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications ［J］. Leukemia, 2014, 28(2): 373383. DOI: 10.1038/leu.2013.174. ［6］ Varettoni M, Corso A, Pica G, et al. Incidence presenting features and outcome of extrameddiary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients［J］. Ann Oncol, 2010, 21(2): 325330. DOI: 10.1093/annonc/mdp329. ［7］ 杨光忠, 陈文明. 以硼替佐米为基础的联合方案治疗110例多发性骨髓瘤患者的疗效分析［J］. 中华医学杂志, 2010, 90(38): 26712674. DOI： 10.3760/cma.j.issn.03762491.2010.38.003. ［8］ Laura R, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma［J］. Eur J Haematol, 2006, 76(5): 405408. DOI: 10.1111/j.09024441.2005.t011EJH2462.x. |
